In TAZ-deficient yeast, deletion of cld1 not only suppresses MLCL accumulation and restores CL content but also rescues its growth and lifespan defects, suggesting that the inhibition of the human homolog of cld1 is a potential strategy to treat Barth syndrome (9, 10). This evidence concerns the gene TAFAZZIN and Barth syndrome.